journal article·2024-10Open access

Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors

Junjun Qiu, Tingting Ren, Qinqin Liu, Qian Jiang, Tong Wu, Leong Chi Cheng, Wenqing Yan, Xinyu Qu, Xiao Han, Keqin Hua

Advanced Science· Volume 11· Issue 38

Abstract

Abstract High‐grade serous tubo‐ovarian cancer (HGSTOC) is an aggressive gynecological malignancy including homologous recombination deficient (HRD) and homologous recombination proficient (HRP) groups. Despite the therapeutic potential of poly (ADP‐ribose) polymerase inhibitors (PARPis) and anti‐PDCD1 antibodies, acquired resistance in HRD and suboptimal response in HRP patients necessitate more precise treatment. Herein, single‐cell RNA and single‐cell T‐cell receptor sequencing on 5 HRD and 3 HRP tumors are performed to decipher the heterogeneous tumor immune microenvironment (TIME), along with multiplex immunohistochemistry staining and animal experiments for validation. HRD tumors are enriched with immunogenic epithelial cells, FGFR1+PDGFRβ+ myCAFs, M1 macrophages, tumor reactive CD8+/CD4+ Tregs, whereas HRP tumors are enriched with HDAC1‐expressing epithelial cells, indolent CAFs, M2 macrophages, and bystander CD4+/CD8+ T cells. Significantly, customized therapies are proposed. For HRD patients, targeting FGFR1+PDGFRβ+ myCAFs via tyrosine kinase inhibitors, targeting Tregs via anti‐CCR8 antibodies/TNFRSF4 stimulation, and targeting CXCL13+ exhausted T cells by blocking PDCD1/CTLA‐4/LAG‐3/TIGIT are proposed. For HRP patients, targeting indolent CAFs, targeting M2 macrophages via CSF‐1/CSF‐1R inhibitors, targeting bystander T cells via tumor vaccines, and targeting epithelial cells via HDAC inhibitors. The study provides comprehensive insights into HRD and HRP TIME and tailored therapeutic approaches, addressing the challenges of PARPi‐resistant HRD and refractory HRP tumors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ovarian cancer diagnosis and treatment · PARP inhibition in cancer therapy · Cancer Genomics and Diagnostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Gynecology Obstetrics and Gynecology Hospital Fudan University 419 Fangxie Road Shanghai 200011 China

Shanghai Key Laboratory of Female Reproductive Endocrine‐Related Diseases 413 Zhaozhou Road Shanghai 200011 China

Kangxiang Bio‐tech.Ltd. 2168 Chenhang Road ShangHai 201114 China

Funding

National Natural Science Foundation of China · Key Technologies Research and Development Program · Science and Technology Innovation Plan Of Shanghai Science and Technology Commission · Shanghai Municipal Hospital Development Center

References (53)

Show source-provided references
1. 10.3322/caac.2166010.3322/caac.21660 ↗
2. 10.20892/j.issn.2095-3941.2016.008410.20892/j.issn.2095-3941.2016.0084 ↗
3. 10.3322/caac.2155910.3322/caac.21559 ↗
4. Coleman R. L. · N. Engl. J. Med. · 2020 · 382 · 686
5. 10.1016/j.annonc.2020.08.210210.1016/j.annonc.2020.08.2102 ↗
6. 10.1016/j.ctrv.2020.10211110.1016/j.ctrv.2020.102111 ↗
7. 10.1016/j.drup.2021.10074410.1016/j.drup.2021.100744 ↗
8. 10.1056/NEJMoa191096210.1056/NEJMoa1910962 ↗
9. 10.1200/JCO.19.0100910.1200/JCO.19.01009 ↗
10. 10.3390/ijms2212653210.3390/ijms22126532 ↗
11. 10.1093/annonc/mdz13510.1093/annonc/mdz135 ↗
12. 10.1016/j.esmoop.2022.10053610.1016/j.esmoop.2022.100536 ↗
13. 10.1001/jamaoncol.2019.104810.1001/jamaoncol.2019.1048 ↗
14. 10.1186/s13045-022-01307-210.1186/s13045-022-01307-2 ↗
15. 10.1038/ncomms1508110.1038/ncomms15081 ↗
16. 10.1038/nbt.293810.1038/nbt.2938 ↗
17. 10.1016/j.ccell.2021.04.00410.1016/j.ccell.2021.04.004 ↗
18. 10.1186/s13073-021-00922-x10.1186/s13073-021-00922-x ↗
19. 10.1038/s41586-022-05496-110.1038/s41586-022-05496-1 ↗
20. 10.1038/s41577-019-0218-410.1038/s41577-019-0218-4 ↗
21. 10.1093/nar/gks111110.1093/nar/gks1111 ↗
22. 10.1016/B978-0-12-394387-3.00003-310.1016/B978-0-12-394387-3.00003-3 ↗
23. 10.1038/s43018-022-00411-z10.1038/s43018-022-00411-z ↗
24. 10.1158/2159-8290.CD-21-171410.1158/2159-8290.CD-21-1714 ↗
25. 10.1038/nri285210.1038/nri2852 ↗
26. 10.1161/CIRCULATIONAHA.120.04652810.1161/CIRCULATIONAHA.120.046528 ↗
27. 10.3389/fimmu.2020.0173110.3389/fimmu.2020.01731 ↗
28. 10.1158/0008-5472.CAN-18-254510.1158/0008-5472.CAN-18-2545 ↗
29. 10.1016/j.cell.2020.03.04810.1016/j.cell.2020.03.048 ↗
30. 10.1038/s41590-022-01267-210.1038/s41590-022-01267-2 ↗
31. 10.1038/s43018-020-00148-710.1038/s43018-020-00148-7 ↗
32. 10.1016/j.molmed.2018.03.00610.1016/j.molmed.2018.03.006 ↗
33. 10.1038/s41586-018-0694-x10.1038/s41586-018-0694-x ↗
34. 10.1038/s43018-021-00292-810.1038/s43018-021-00292-8 ↗
35. 10.1038/s43018-022-00433-710.1038/s43018-022-00433-7 ↗
36. 10.1158/0008-5472.CAN-20-358510.1158/0008-5472.CAN-20-3585 ↗
37. 10.1038/s41571-019-0175-710.1038/s41571-019-0175-7 ↗
38. 10.1186/s13073-019-0684-010.1186/s13073-019-0684-0 ↗
39. 10.1186/s12943-021-01428-110.1186/s12943-021-01428-1 ↗
40. 10.1158/1078-0432.CCR-22-103110.1158/1078-0432.CCR-22-1031 ↗
41. 10.1002/cac2.1241410.1002/cac2.12414 ↗
42. 10.1186/s12943-020-01234-110.1186/s12943-020-01234-1 ↗
43. 10.1136/thoraxjnl-2021-21700110.1136/thoraxjnl-2021-217001 ↗
44. 10.1016/j.ccr.2014.05.01610.1016/j.ccr.2014.05.016 ↗
45. 10.1126/science.aax024910.1126/science.aax0249 ↗
46. 10.1038/s41586-018-0698-610.1038/s41586-018-0698-6 ↗
47. 10.1038/7555610.1038/75556 ↗
48. 10.1101/gr.620260710.1101/gr.6202607 ↗
49. 10.1371/journal.pcbi.100689910.1371/journal.pcbi.1006899 ↗
50. 10.1038/s41598-020-59671-310.1038/s41598-020-59671-3 ↗
51. 10.1038/bjc.2012.45110.1038/bjc.2012.451 ↗
52. 10.1002/ijc.2982910.1002/ijc.29829 ↗
53. 10.1016/j.archoralbio.2017.03.01410.1016/j.archoralbio.2017.03.014 ↗